# Efficacy and Safety of BIIB111 for the Treatment of Choroideremia

> **NCT03496012** · PHASE3 · COMPLETED · sponsor: **Biogen** · enrollment: 169 (actual)

## Conditions studied

- Choroideremia

## Interventions

- **GENETIC:** BIIB111

## Key facts

- **NCT ID:** NCT03496012
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-11
- **Primary completion:** 2020-12-01
- **Final completion:** 2020-12-01
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2023-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03496012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03496012, "Efficacy and Safety of BIIB111 for the Treatment of Choroideremia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03496012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*